Press Release (ePRNews.com) - Rochester, NY - Nov 29, 2018 - A recent study looking at digital patient recruitment for clinical trials found that social media in particular offers significant upside when it comes to usability for trial education and ultimately, enrollment. The study, “Content That Clicks: Effective Social Marketing for Clinical Trial Recruitment,” undertaken by Syneos Health Communications, revealed a number of trial advertising themes that when taken into consideration may lead to better recruitment outcomes.
For example, when it comes to whether or not a patient can recall seeing trial advertisements, more than 66 percent of respondents in the survey remembered reading about a study opportunity. Perhaps more importantly the research found that “high trial intenders” are individuals who report serious interest in a trial, to the point of having an intention to enroll.
This is the exact scenario that newcomer iPatientAxis is successfully maximizing for CROs, sponsors, and recruitment firms around the globe. When a patient makes an overture expressing intent, time is of the essence for scheduling the screening visit. But without relevant medical history in the hands of the site at the time of the patient visit, the screening procedure will be limited, the visit may need to be re-scheduled, or redundant testing may be performed, driving cost. All of these may negatively affect the overall experience of the potential volunteer, lessening the likelihood of enrollment.
“At the risk of sounding a bit clichéd, iPatientAxis has based its trial support model on a simple tenet: strike will the iron is hot. Anyone that works in the trial recruitment space knows the stats well – that enrollment is costly, with upwards of one-third of a trial budget allocated to that front-end piece. As delays are introduced due to under-performance, sponsors stand to lose millions of dollars,” offered Paul Mitchel, a consultant in the clinical trial recruitment space. Mitchel knows firsthand how the right data applied at the right time accelerates the screening process at a time when a potential participant is showing full engagement in a study opportunity.
iPatientAxis combines years of medical records retrieval, aggregation, and indexing with subject matter expertise in feasibility and eligibility reviews. Easy-to-use, digital authorization forms expedite the initiation of the record request process for an interested individual; a fully electronic, closed-loop data transmission system preserves the security and integrity of collected data as it is en-route to the site performing the screening.
After data is reviewed for quality and packaged up for the site personnel to easily digest, the iPatientAxis team takes things a step further by adding record elements into a customer-level database for leverage downstream in support of any future trial needs in the same therapeutic area.
The impact of iPatientAxis’ unique service offering has been demonstrated across therapeutic areas that are both general and specialized in nature. In trials targeting pain to gastroenterological conditions to women’s health, when iPatientAxis assumed responsibility for obtaining data to inform trial screening, enrollment improved from between 150-500% as a result of a streamlined process with built-in automation to assess eligibility.
“It’s fascinating to read about the newer and more social approaches to patient recruitment that are showing impact. But without a way to rapidly capitalize on an individual’s expressed interest and intent, there are too many opportunities for noise to interfere and distract,” concluded Mitchel.
iPatientAxis is the leader in patient identification and qualification services for the life sciences industry. Uniquely positioned to change the paradigm in the global clinical trial market, iPatientAxis combines real-world clinical data with a patented platform to streamline and automate both patient and site identification. iPatientAxis ensures that trials meet their enrollment goals without incurring the unexpected expenses of adding additional sites or costly delays. To learn more visit www.ipatientaxis.com.
Press Contact: Tess Dokus, firstname.lastname@example.org Source :